Cosentyx Clears the Bar in Polymyalgia Rheumatica

Polymyalgia rheumatica (PMR) is a common but under-discussed autoimmune condition that causes sudden, often severe stiffness and aching in the shoulders, neck, and hips, usually in people over 50. Standard treatment has long relied on steroids like prednisone, which work well at first but come with a heavy cost: many patients stay on them for a year or more, and long-term steroid use raises the risk of bone loss, high blood sugar, weight gain, and other side effects. Until now, there hasn't been a steroid-sparing drug with strong trial evidence behind it for this specific disease.

That changed with the REPLENISH trial, a Phase 3 study run across 27 countries and simultaneously published in the New England Journal of Medicine on June 3, 2026. Researchers randomized patients with PMR to receive secukinumab (marketed as Cosentyx), an antibody that blocks a signaling protein called IL-17A, at either a 300mg or 150mg dose, or a placebo, all alongside a standard 24-week steroid taper. Secukinumab is already approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis, so this trial tested whether the same drug could help a different, though related, inflammatory condition.

The results were striking. Roughly 41% of patients in both the 300mg and 150mg secukinumab groups reached sustained remission by week 52, compared to about 20% of patients on placebo, meaning the drug essentially doubled the chance of durable disease control. Just as important for patients living with the daily reality of steroid side effects, those on secukinumab were able to taper off steroids meaningfully faster than those on placebo, and the benefit held up through a full year of follow-up rather than fading over time.

For a condition that has mostly been managed with a decades-old, blunt-instrument approach, having a targeted biologic with this kind of head-to-head data is a meaningful shift. Novartis, which makes Cosentyx, has already filed for regulatory approval of this new indication in the United States, European Union, and Japan, which means PMR patients could realistically see this option reach pharmacies within the next year or two if regulators sign off.

It's worth being clear about what this trial does and doesn't show. This was a placebo-controlled trial specifically in PMR, not a head-to-head comparison against other steroid-sparing drugs already used off-label for the condition, like methotrexate or tocilizumab. And as with any biologic, secukinumab carries its own set of risks and side effects that your rheumatologist will want to walk through individually. But for a disease that hasn't had a lot of new options in a long time, sustained remission in roughly four in ten patients, with a real path off steroids, is genuinely good news.

If you or someone you love lives with PMR, this is worth bringing up at your next rheumatology appointment, especially if steroid side effects have become their own quality of life problem. Regulatory review timelines vary, so ask your doctor whether this might become an option for your specific case once it's approved.